Gencove gets SIBR grant to validate polygenic risk scores

Genome sequencing company Gencove received a $330,000 Phase I grant to validate polygenic risk score estimations from sequencing data to predict disease risk, with a first application in coronary heart disease. The grant was awarded to Gencove Inc. (New York, N.Y.) under the Small Business Innovation Research (SBIR) program of NIH's National Human Genome Research Institute...